Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Gains from Investment Securities: 2011-2024

Historic Gains from Investment Securities for Abeona Therapeutics (ABEO) over the last 13 years, with Dec 2024 value amounting to $584,700.

  • Abeona Therapeutics' Gains from Investment Securities fell 97.39% to $394,921 in Q3 2025 from the same period last year, while for Sep 2025 it was $394,921, marking a year-over-year decrease of 98.64%. This contributed to the annual value of $584,700 for FY2024, which is 226.65% up from last year.
  • According to the latest figures from FY2024, Abeona Therapeutics' Gains from Investment Securities is $584,700, which was up 226.65% from $179,001 recorded in FY2023.
  • Over the past 5 years, Abeona Therapeutics' Gains from Investment Securities peaked at $584,700 during FY2024, and registered a low of -$11.4 million during FY2022.
  • Its 3-year average for Gains from Investment Securities is -$3.5 million, with a median of $179,001 in 2023.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first crashed by 162,714.29% in 2022, then surged by 226.65% in 2024.
  • Abeona Therapeutics' Gains from Investment Securities (Yearly) stood at $127,000 in 2020, then crashed by 94.49% to $7,000 in 2021, then slumped by 162,714.29% to -$11.4 million in 2022, then surged by 101.57% to $179,001 in 2023, then skyrocketed by 226.65% to $584,700 in 2024.